Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
- Publicatie datum 06 nov 2014 - 07:36
- Statutaire naam Galapagos N.V.
- Titel GSK discloses good efficacy in psoriasis with GSK2856184
- Bericht Mechelen, Belgium; 6 November 2014: Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that GSK has disclosed on its website the Phase 2 psoriasis study results with selective JAK1 inhibitor GSK2856184, licensed from Galapagos. The results show higher efficacy than those published for apremilast, a recently approved oral medicine for psoriasis and psoriatic arthritis. GSK completed a multi-center study with GSK2586184 in 56 subjects with moderate to severe plaque-type psoriasis. In a double-blind and placebo controlled study in 13 centers in Germany and the United Kingdom, patients received either 100, 200, or 400 mg GSK2586184 BID, or placebo BID. The treatment period was up to 12 weeks. Each patient had 7 visits: baseline, at the start of treatment, after weeks 2, 4, and 8, at the end of treatment after 12 weeks, and a follow up at week 16.
|201411060000000004_GSK discloses good efficacy in psoriasis with GSK2856184.pdf|
|201411060000000004_GSK publiceert goede werkzaamheid van GSK2856184 bij psoriasis.pdf|
Datum laatste update: 22 januari 2022